CN1861114A - Application of Qishen Yidripping pills for preparing medicine for preventing and treating high-altitude oxygen deficit - Google Patents

Abstract

The invention relates to the application of Qishen Yiqi dripping pills in the preparation of medicines for preventing and treating plateau hypoxia. Through the experiment of Qishen Yiqi Dropping Pills on the MDA and lactic acid content in the brain tissue and blood of simulated plateau hypoxic rats, it was shown that Qishen Yiqi Dropping Pills can inhibit the content of lactic acid and MDA in the brain tissue and blood under hypoxic conditions increase, indicating that Qishen Yiqi Dropping Pills can be used to prevent and treat plateau hypoxia.

Description

Application of Qishen Yiqi Dropping Pills in Preparation of Drugs for Prevention and Treatment of Plateau Hypoxia

technical field

The invention belongs to the field of medicine, and in particular relates to the application of Qishen Yiqi dripping pills in the preparation of medicines for preventing and treating plateau hypoxia.

Background technique

Hypoxia caused by insufficient oxygen supply in the plateau environment can cause changes in human body functions, metabolism, and morphology, which can be life-threatening in severe cases. When ordinary people step into a plateau environment for the first time, there will be adaptive compensatory reactions of various organs and tissues of the human body, such as deepening and accelerating breathing, increasing heart rate, contraction of blood vessels such as skin, stomach, intestines and kidneys, and dilation of cerebral blood vessels and coronary arteries, etc. If the normal metabolic needs of the human body cannot be maintained through the above compensation, artificial oxygen inhalation and other treatments are required. If the hypoxia cannot be corrected, each nerve center will enter a state of inhibition due to the hypoxia of the central nervous system, resulting in shallower and slower breathing, decreased heart rate and cardiac output, pulmonary edema, and plateau red blood cells. Syndrome, myocardial infarction, cerebral thrombosis, cerebral edema, and even death. Most people can gradually adapt to plateau hypoxia through self-regulation, and only a small number of people will produce a series of clinical manifestations. Nevertheless, early prevention and treatment of plateau hypoxia is still very important.

Qishen Yiqi Dropping Pills are composed of Astragalus, Danshen, Panax notoginseng and Jiangxiang, and are used to treat angina pectoris of coronary heart disease of Qi deficiency and blood stasis type. Chinese patent CN1375316A discloses the composition, preparation method and application of the preparation in angina pectoris of coronary heart disease, but the effect of the medicine in preventing and treating plateau hypoxia has not been reported yet.

Contents of the invention

The object of the present invention is to provide the application of Qishen Yiqi dripping pills in the preparation of medicines for preventing and treating plateau hypoxia.

The Qishen Yiqi dripping pill is prepared from the following components according to weight percentage: astragalus 22.2%-66.8%, salvia miltiorrhiza 11.6%-33.4%, notoginseng 2.5%-13.5%, and jiangxiang 14.5%-44.3%. The optimal ratio is astragalus 44.7%, salvia miltiorrhiza 26.7%, notoginseng 6.3%, and jiangxiang 22.3%; or astragalus 41.2%, salvia miltiorrhiza 23.8%, notoginseng 4.5%, and jiangxiang 30.5%.

In order to better understand the present invention, the following experiments on the effects of Qishen Yiqi dripping pills on the brain tissue of hypoxic rats at a simulated altitude of 7500 meters and blood malondialdehyde (MDA), lactic acid content illustrate that Qishen Yiqi drops The role of pills in the prevention and treatment of plateau hypoxia.

1. Method

1. Animal treatment: (1) 30 SD rats, weighing 180-200g, were randomly divided into normoxia control group (n=10), acute hypoxia group (n=10), Qishen Yiqi dripping pills Oxygen group (n=10). The Qishen Yiqi Dropping Pill plus hypoxia group was given 0.8ml/100g body weight (that is, 30mg Qishen Yiqi Dropping Pill/100g body weight, dissolved in water) once a day for 7 consecutive days; volume of water. (2) Decompression method: the animals in the acute hypoxia group and the Qishen Yiqi dripping pill plus hypoxia group were placed in a hypobaric chamber one hour after the last administration, and rose to an altitude of 7,500 meters at a speed of 10 m/s. lasted for 7 hours; the normoxia control group was kept without any treatment and kept at room temperature in normoxia. After leaving the cabin, the animals in each group were quickly decapitated and their brains were stripped, and blood was collected. One half of the brain was used to measure the water content of the brain, and the other half of the brain was weighed and added to 0-4°C physiological saline at a ratio of 1:20 (w/v) to make a 5% brain homogenate. Blood was centrifuged to obtain serum.

2. Determination of brain water content: using dry-wet mass method, hemibrain tissue of each group was placed in a weighing bottle, weighed and dried in an oven at 50°C until constant weight. The brain water content was calculated according to the formula: brain water content (%)=(wet weight-dry weight)/wet weight×100%.

3. Biochemical determination: Determination of brain homogenate protein content by Folin-phenol method. 100 μl of 5% brain homogenate and 100 μl of serum were taken to determine the MDA content; the MDA content in tissue was expressed in nmol/mgprot, and the MDA content in serum was expressed in nmol/ml. Take 10 μl of 5% brain homogenate and 10 μl of serum to measure the content of lactic acid; the content of lactic acid in tissue is expressed in μmol/mgprot, and the content of lactic acid in serum is expressed in mmol/L.

4. Statistical method: the experimental results of each group are used x ± s means that the difference between the means of each group is compared by t test.

2. Results

1. Changes in water content, MDA and lactic acid content of brain tissue homogenate (see Table 1)

The brain water content in the acute hypoxia group was significantly higher than that in the normoxia control group (P<0.01), and the MDA and lactic acid contents were significantly increased (P<0.01); The content was significantly lower than that in the acute hypoxia group (P<0.05 or P<0.01).

Table 1 Changes of water content, MDA and lactic acid content in brain tissue homogenate (x±s) group Moisture content (%) MDA (nmol/mgprot) Lactic acid (μmol/mgprot) normoxia control group 78.06±0.192 6.042±0.845 0.155±0.034 acute hypoxia group 78.71±0.221 ^** 7.483±0.747 ^** 0.239±0.041 ^** Qishen Yiqi dripping pill plus hypoxia group 78.38±0.281 ^**## 6.753±0.426 ^*# 0.178±0.039 ^##

Note: Compared with the normoxia control group, ^* P<0.05 ^** P<0.01

Compared with the acute hypoxia group, ^# P＜0.05 ^## P＜0.01

2. Changes of MDA and lactic acid content in serum (see Table 2)

The serum MDA and lactic acid contents in the acute hypoxia group were significantly higher than those in the normal oxygen control group (P<0.01), and the serum MDA and lactic acid contents in the Qishen Yiqi dripping pills plus hypoxia group were significantly lower than those in the acute hypoxia group (P<0.01 ).

Table 2 Changes of MDA and lactic acid content in serum (x±s) group MDA (nmol/ml) Lactic acid (mmol/L) normoxia control group 7.562±0.985 9.414±1.122 acute hypoxia group 10.138±1.241 ^** 10.987±1.124 ^** Qishen Yiqi dripping pill plus hypoxia group 7.112±0.973 ^## 8.763±1.257 ^##

Note: Compared with the normoxia control group, ^* P<0.05 ^** P<0.01

Compared with the acute hypoxia group, ^# P＜0.05 ^## P＜0.01

Hypoxia induces enhanced anaerobic glycolysis of glucose in brain tissue and blood and increased lactic acid production. The accumulation of lactic acid in tissues will lead to increased cell osmotic pressure, mitochondrial swelling and rupture, affecting mitochondrial respiratory function and resulting in energy metabolism disorders. During hypoxia, the generation of intracellular lactic acid, oxygen free radicals and lipid peroxides increases, which will damage the energy metabolism of mitochondria, and the intracellular ATP level will decrease. In the above experiments, the content of lactic acid and MDA in brain tissue and blood of rats significantly increased after exposure to hypoxia, and the pre-administration of Qishen Yiqi Dropping Pills before hypoxia could inhibit the increase of lactic acid and MDA content. This result shows that Qishen Yiqi dripping pills have the ability to promote ATP production and can be used to prevent and treat plateau hypoxia.

Detailed ways

The medicine of the present invention will be further described below in conjunction with the examples, and the following examples are only used to illustrate the present invention rather than limit the present invention.

Embodiment one

Take 86.5g of Radix Astragali, 21.3g of Salvia Miltiorrhiza, 3.5g of Panax notoginseng, 20.6g of Jiangxiang, and 30g of polyethylene glycol-6000 as an auxiliary material. Decoct the crushed salvia miltiorrhiza and Panax notoginseng in water twice, adding 7 times the amount of water each time for 2 hours each time, combining the decoction liquid, filtering, and concentrating the filtrate to 900ml, adding 95% ethanol to make the alcohol concentration reach 70%, let it stand for 12-24 hours, filter, recover ethanol, concentrate into an extract with a relative density of 1.32-1.38 (50-60°C); decoct the pulverized Astragalus membranaceus twice with water, adding 6 Double the amount of water, extract for 2 hours and 1 hour in turn, combine the filtrate, and when concentrated to about 1500ml, add 95% ethanol to make the alcohol concentration 60%, let it stand for 12-24 hours, filter, recover ethanol from the filtrate, and concentrate to about 400ml , add 95% ethanol to make the alcohol concentration 80%, let it stand for 12 to 24 hours, filter, reclaim the ethanol from the filtrate, and concentrate it into an extract with a relative density of 1.32 to 1.38 (50 to 60°C); 5 times the amount of water, reflux for extraction for 5 hours, and collect the volatile oil; take the above-mentioned Danshen Sanqi extract, Astragalus extract, and polyethylene glycol-6000, dissolve in a water bath, and after homogenization, add the balsamic volatile oil, mix well, and move to the drop In the pill machine, make 1000 drop pills.

Embodiment two

Get Astragalus 40.6g, Salvia miltiorrhiza 44.8g, Radix Notoginseng 11.2g, Dalbergia 38.6g, adjuvant Polyethylene Glycol-6000 30g, the preparation technology of embodiment 1 is made Chinese medicine preparation of the present invention.

Embodiment Three

Get Radix Astragali 77.3g, Salvia Miltiorrhiza 22.8g, Radix Notoginseng 4.8g, Dalbergia 30.5g, adjuvant Polyethylene Glycol-6000 28g, make Chinese medicine preparation of the present invention by the preparation technology of embodiment 1.

Embodiment Four

Get Radix Astragali 42.3g, Salvia Miltiorrhiza 39.2g, Radix Notoginseng 8.2g, Dalbergia 46.8g, adjuvant Polyethylene Glycol-6000 25g, make Chinese medicine preparation of the present invention by the preparation technology of embodiment 1.

Embodiment five

Get Radix Astragali 65.2g, Salvia Miltiorrhiza 38.9g, Radix Notoginseng 9.3g, Radix Dalbergia 32.5g, adjuvant Polyethylene Glycol-6000 40g, make Chinese medicine preparation of the present invention by the preparation technology of embodiment 1.

Embodiment six

Get Radix Astragali 56.2g, Salvia Miltiorrhiza 32.5g, Radix Notoginseng 6.2g, Dalbergia 41.6g, adjuvant Polyethylene Glycol-6000 22g, make Chinese medicine preparation of the present invention by the preparation technology of embodiment 1.

Embodiment seven

Get Radix Astragali 36.5g, Salvia Miltiorrhiza 32.4g, Radix Notoginseng 6.2g, Dalbergia 41.7g, adjuvant Polyethylene Glycol-6000 22g, make Chinese medicine preparation of the present invention by the preparation technology of embodiment 1.

Embodiment Eight

Get Radix Astragali 65.6g, Salvia Miltiorrhiza 25.8g, Panax notoginseng 9.5g, Dalbergia 46.4g, adjuvant Polyethylene Glycol-6000 35g, make Chinese medicine preparation of the present invention by the preparation technology of embodiment 1.

Embodiment nine

Get Radix Astragali 35.5g, Salvia Miltiorrhiza 50.8g, Radix Notoginseng 16.3g, Radix Dalbergia 52.3g, adjuvant Polyethylene Glycol-6000 35g, make Chinese medicine preparation of the present invention by the preparation technology of embodiment 1.

Claims (4)

1. The application of Qishen Yiqi dripping pills in the preparation of drugs for the prevention and treatment of plateau hypoxia. 2. the application of Qishen Yiqi Dropping Pills according to claim 1 in the preparation of medicines for preventing and treating plateau hypoxia, is characterized in that, said Qishen Yiqi Dropping Pills is prepared from the following components by weight percentage: Astragalus 22.2% to 66.8%, Salvia miltiorrhiza 11.6% to 33.4%, Panax notoginseng 2.5% to 13.5%, Dalbergia 14.5% to 44.3%. 3. the application of Qishenyiqi dripping pills according to claim 2 in the preparation of medicines for preventing and treating plateau hypoxia, characterized in that, said Qishenyiqi dropping pills are prepared from the following components by weight percentage: Astragalus 44.7%, Salvia miltiorrhiza 26.7%, Panax notoginseng 6.3%, Dalbergia 22.3%. 4. the application of Qishen Yiqi Dropping Pills according to claim 2 in the preparation of medicines for preventing and treating plateau hypoxia, is characterized in that, said Qishen Yiqi Dropping Pills is prepared from the following components by weight percentage: Astragalus 41.2%, Salvia miltiorrhiza 23.8%, Panax notoginseng 4.5%, Dalbergia 30.5%.